MGMT and central nervous system cancer: Other studies with different approaches, defined the potential use of radiomics on FET-PET imaging to differentiate MS from glioma II°–IV° or on 18F-DOPA-PET to predict pathologic Methylation of the O6-methylguanine methyltransferase (MGMT) gene promoter status in gliomas [43,44].